Prospective, Single-center, Open-label, Pilot Study Using Cryopreserved Umbilical Tissue Containing Viable Cells in the Treatment of Complex Acute and Chronic Wounds

被引:0
|
作者
Mullins, Robert F. [1 ]
Hassan, Zaheed [1 ]
Homsombath, Bounthavy [1 ]
Fagan, Shawn [1 ]
Craft-Coffman, Beretta [1 ]
Wilson, Joan [2 ]
Rumbaugh, John G. [2 ]
Saunders, Molly [3 ]
Danilkovitch, Alla [3 ]
机构
[1] Joseph M Still Res Fdn, JMS Burn Ctr, Augusta, GA USA
[2] Joseph M Still Res Fdn, Augusta, GA USA
[3] Osiris Therapeut Inc, Columbia, MD 21046 USA
关键词
viable; cryopreserved; umbilical tissue; complex; wound; VACUUM-ASSISTED CLOSURE; DIABETIC FOOT ULCERS; THERAPY; MANAGEMENT; MEMBRANE;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction. Complex wounds with exposed bone, muscle, tendon, or hardware continue to be a therapeutic challenge for wound care providers. Wounds with exposed structures are more susceptible to infection, necrosis, and amputation. As such, rapid granulation to cover exposed deep tissue structures is essential for patient recovery. Objective. In this prospective, pilot study, the authors evaluate the clinical outcomes of a cryopreserved umbilical tissue graft containing viable cells (vCUT) in the treatment of complex wounds. Materials and Methods. Ten patients with 12 wounds each received 1 application of vCUT. Two patients did not complete the study and were removed from the per-protocol population. Data analyses were performed on the remaining 8 patients with 10 wounds. The average wound area was 16.5 cm(2) with an average duration of 10 months. Post-application, patients were followed for an additional 4 weeks for granulation, closure, and safety outcomes. Results. By the end of the study, 8 of 10 (80.0%) vCUT-treated wounds achieved 100% granulation, and 3 wounds (30.0%) went on to achieve complete closure. The median area reduction was 40.5% and the median volume reduction was 59.4%. Conclusions. The results of this study suggest vCUT in conjunction with standard of care can be a viable treatment option for acute and chronic lower extremity complex wounds.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [31] Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis
    Moul, Danielle K.
    Routhouska, Shannon B.
    Korman, Neil J.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2007, 11 (04) : 132 - 136
  • [32] Effect of Erythropoietin-stimulating agent on uremic neuropathy in hemodialysis patients: a single-center open-label prospective study
    Khafagi, Amal T.
    Yehia, Mohamed A.
    Helmy, Amal K.
    Hassan, Waleed
    Abdelhakim, Nashwa
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2022, 58 (01):
  • [33] Targeting Bruton's tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
    Guan, Wenxue
    Wang, Liang
    Peng, Xiaoyan
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [34] Safety and efficacy of cathodal transcranial direct current stimulation in patients with Lennox Gastaut Syndrome: An open-label, prospective, single-center, single-blinded, pilot study
    San-Juan, Daniel
    Ruiz, Axel Galindo
    Arriola, Armando Baigts
    Pesqueira, Gerardo Quinones
    Ruffini, Giulio
    Trenado, Carlos
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2022, 100 : 44 - 50
  • [35] Intra-Articular Hybrid Hyaluronic Acid Injection Treatment in Overweight Patients with Knee Osteoarthritis: A Single-Center, Open-Label, Prospective Study
    Scaturro, Dalila
    Vitagliani, Fabio
    Terrana, Pietro
    Cuntrera, Daniele
    Falco, Vincenzo
    Tomasello, Sofia
    Mauro, Giulia Letizia
    APPLIED SCIENCES-BASEL, 2021, 11 (18):
  • [36] A single center, open-label, pilot study evaluating the safety and effectiveness of efalizumab in the treatment of oral lichen planus
    Graves, J
    Smith, D
    Heffernan, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB64 - AB64
  • [37] Canakinumab for Behcet's Disease Resistant to Standard Treatment (CanBeDisT) - an open-label single center pilot study
    Koetter, I.
    Deuter, C.
    Henes, J.
    Xenitidis, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : S187 - S187
  • [38] A prospective single-center, single-arm, open-label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
    Duan, Hongtao
    Wang, Zhaoyang
    Cao, Lili
    Zhu, Yifang
    Tong, Liping
    Yan, Xiaolong
    THORACIC CANCER, 2024, 15 (19) : 1471 - 1476
  • [39] Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure
    Fujisue, Koichiro
    Ito, Miwa
    Matsuzawa, Yasushi
    Arima, Yuichiro
    Takashio, Seiji
    Sueta, Daisuke
    Araki, Satoshi
    Hanatani, Shinsuke
    Yamanaga, Kenshi
    Yamamoto, Masahiro
    Kaneko, Shozo
    Yamamoto, Eiichiro
    Matsushita, Kenichi
    Soejima, Hirofumi
    Tsujita, Kenichi
    CIRCULATION REPORTS, 2024, 6 (03) : 55 - 63
  • [40] Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis: A Single-Center Open-Label Prospective Study
    Sugimoto, Shinya
    Naganuma, Makoto
    Kiyohara, Hiroki
    Arai, Mari
    Ono, Keiko
    Mori, Kiyoto
    Saigusa, Keiichiro
    Nanki, Kosaku
    Takeshita, Kozue
    Takeshita, Tatsuya
    Mutaguchi, Makoto
    Mizuno, Shinta
    Bessho, Rieko
    Nakazato, Yoshihiro
    Hisamatsu, Tadakazu
    Inoue, Nagamu
    Ogata, Haruhiko
    Iwao, Yasushi
    Kanai, Takanori
    DIGESTION, 2016, 93 (03) : 193 - 201